ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "ASH 2025"
Episode Synopsis
ASH 2025 Highlights:
MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma
Paradigm: HMA + Ven vs. 7+3 or CPX-351
Denosumab safety & dosing in Multiply Myeloma and renal dysfunction
Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?
MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma
Paradigm: HMA + Ven vs. 7+3 or CPX-351
Denosumab safety & dosing in Multiply Myeloma and renal dysfunction
Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust